Prijevremeni porođaj
DOI:
https://doi.org/10.5457/ams.v47iSup%201.421Keywords:
prematurelabour, premature rupture of membranes, corticosteroids.Abstract
Pretem labour continues to represent one of the most significant problem in perinatal medicine, primarily because of its high participation in the perinatal morbidity and mortality. Is defined as delivery prior to 37 weeks of gestation. The lower limit is usually taken 24 gestational weeks. The incidence in many countries around 7-10%. The causes of premature birth can be divided into: fetal, placental, uterine, maternal and other causes. Many microbiological and histopathological studies established that infection occurs in 25 to 40% of preterm labour. A preterm labour in most cases is result of preterm premature rupture of membranes. It occurs in about 40% of preterm births. Estrogen and progesterone play a major role in the endocrinology of pregnancy. Progesterone maintains the myometrium at rest, does not lead to creation of a "gap junction" inhibiting the formation and maturation of cervix. Estrogens contribute to the increase in contractility and excitability of the uterus as well as in induction of cervical ripening prior to the birth. The goal of tocolytic therapy is to stop the activity of the uterus and allow the extension of pregnancy and intrauterine fetal development, to improve perinatal outcome, without endangering the mother. Certain forms of tocolytic therapy can delay delivery for several days, allowing the full effect of corticosteroid therapy and transport the mother to a tertiary center. Inclusion corticosteroids to mother in the period 24-34 weeks of gestation leads to a reduction in perinatal morbidity and mortality.
Keywords: prematurelabour, premature rupture of membranes, corticosteroids.
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
